BioVie Inc
NASDAQ:BIVI
BioVie Inc
BioVie, Inc. is a biopharmaceutical company, which discovers, develops and commercializes drug therapies for liver disease. The company is headquartered in Santa Monica, California. The company went IPO on 2014-01-14. The firm is focused on developing and commercializing BIV201 (continuous infusion terlipressin) an approach to the treatment of ascites due to chronic liver cirrhosis. BIV201 also has an Orphan Drug designation for the treatment of hepatorenal syndrome (HRS). The firm is developing BIV201, a treatment option for patients suffering from ascites and other life-threatening complications of advanced liver cirrhosis caused by hepatitis, nonalcoholic steatohepatitis (NASH) and alcoholism. The firm is also engaged in developing NE3107, an ERK inhibitor that selectively reduces neuroinflammation and insulin resistance.
BioVie, Inc. is a biopharmaceutical company, which discovers, develops and commercializes drug therapies for liver disease. The company is headquartered in Santa Monica, California. The company went IPO on 2014-01-14. The firm is focused on developing and commercializing BIV201 (continuous infusion terlipressin) an approach to the treatment of ascites due to chronic liver cirrhosis. BIV201 also has an Orphan Drug designation for the treatment of hepatorenal syndrome (HRS). The firm is developing BIV201, a treatment option for patients suffering from ascites and other life-threatening complications of advanced liver cirrhosis caused by hepatitis, nonalcoholic steatohepatitis (NASH) and alcoholism. The firm is also engaged in developing NE3107, an ERK inhibitor that selectively reduces neuroinflammation and insulin resistance.
